©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response
Reina Sasaki, Tatsuo Kanda, Naoya Kato, Osamu Yokosuka, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan
Tatsuo Kanda, Mitsuhiko Moriyama, Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Itabashi-ku 173-8610, Japan
Author contributions: All authors contributed to all aspects of this paper.
Conflict-of-interest statement: Sasaki R, Yokosuka O and Moriyama M declare no conflict of interest related to this publication. Kanda T reports grants and other from Abbvie, grants and other from MSD K.K., grants and other from Chugai Pharmaceutical CO., LTD., grants from Sysmex, other from Gilead Sciences, other from Bristol-Myers Squibb, other from Otsuka Pharmaceutical, grants from Daiichi-Sankyo, grants from Shionogi, other from PharmaEssentia, outside the submitted work. Kato N reports grants and other from Abbvie, grants and other from MSD K.K., grants and other from Chugai Pharmaceutical CO., LTD., grants and other from Mitsubishi Tanabe Pharma, grants and other from Gilead Sciences, grants and other from Bristol-Myers Squibb, outside the submitted work.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Tatsuo Kanda, MD, PhD, Associate Professor, Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Tokyo, Itabashi-ku 173-8610, Japan. email@example.com
Telephone: +81-3-39728111 Fax: +81-3-39568496
Received: September 13, 2018
Peer-review started: September 13, 2018
First decision: October 5, 2018
Revised: November 8, 2018
Accepted: November 15, 2018
Article in press: November 16, 2018
Published online: December 27, 2018
Hepatocellular carcinoma (HCC) is the sixth most common cancer type and the third most likely cause of cancer related deaths. HCC is associated with chronic liver disease and cirrhosis in > 90% of cases. In the West and Japan, hepatitis C virus (HCV) infection is one of the leading causes of chronic hepatitis, cirrhosis, and HCC. HCV affects approximately 130-210 million people worldwide, or 2%-3% of the world’s population. Approximately 20%-30% of chronically HCV infected patients show liver cirrhosis, and 1%-4% of cirrhotic patients develop HCC per year. HCC is characterized by a 5-year survival rate of 10%-12%.
Recently, several regimens of direct-acting antiviral (DAA) combinations have been developed for the treatment of chronic HCV infection. The introduction of DAA agents has improved sustained virologic response (SVR) rates to approximately 90% and shortened treatment duration. DAAs also help to overcome interferon non-responsiveness. SVR is associated with improved overall survival in HCV infected patients. Recurrence-free survival in HCV infected patients who have undergone resection or locoregional therapy for HCC is also improved by SVR.
According to studies from the interferon era, the survival beneﬁt in HCC patients infected with HCV has been postulated to occur through anti-inﬂammatory, antiangiogenic, and antiviral properties, and interferon-based antiviral therapies were associated with improved outcomes in HCC patients who were infected with HCV during long-term observation[12,13]. However, treatment with DAA therapy can promptly eradicate serum HCV ribose nucleic acid (RNA), and liver failure, including HCC, may occur after the achievement of SVR. In 2016, two articles suggested an unexpectedly higher rate of early occurrence and recurrence of HCC in HCV-infected patients who were treated with DAAs[15,16]. Both had relatively shorter-term follow-up periods after the end of treatment (EOT). However, several articles presenting the opposite data or the data from longer-term follow-up periods have been published. A conclusion has not been reached in this matter and several studies are still ongoing. Considering these circumstances, this report focuses on hepatocarcinogenesis after DAA treatment, which will be discussed based on clinical points of view.
HCC OCCURRENCE AND RECURRENCE AFTER SVR BY DAA TREATMENT
Interferon-free regimens with DAA combination can be used to treat HCV-infected individuals who cannot be treated with interferon-based regimens, such as older patients, patients with comorbidities, patients with cirrhosis, or patients with a history of HCC. HCC recurrence or HCC occurrence, respectively, has been defined as the appearance of HCC in a patient with or without history of HCC .
In general, HCV infected patients with advanced liver fibrosis tend to develop HCC, compared to those with mild or moderate liver fibrosis. Patients whose HCC has been curatively treated, also have a much higher risk of recurrence of HCC.
In 2016, Conti et al reported that DAA therapy induced SVR in 91% of patients. During a 24-wk follow-up, HCC occurrence and recurrence, respectively, were detected in 9 of 285 patients (3.16%) and in 17 of 59 patients (28.8%); a total of 26 patients developped HCC. They also demonstrated that neither HCV genotype nor therapeutic DAA regimen correlated to HCC occurrence or HCC recurrence. Similarly, Reig et al reported an unexpectedly high rate and pattern of tumor recurrence coinciding with HCV clearance, suggesting the possible disruption of immune tumor surveillance. In their study, 8 (13.8%), 45 (77.6%), 2 (3.4%), 3 (5.2%) patients were HCV genotypes 1a, 1b, 3 and 4, respectively.
Guarino et al extensively reviewed the association between DAA and HCC in patients with chronic HCV infection. They reported that, among 11 and 18 studies, the HCC occurrence and recurrence rates ranged from 0 to 7.4% and from 0 to 54.4%, respectively, although their observation periods were relatively shorter.
Li et al reported that the short-term incidence of HCC is not increased after the eradication of HCV with DAA and mentioned that the previous reports about higher rates of HCC associated with DAAs may be related to the fact that those patients had a higher risk of developing HCC. Notably, this study also suggests that some patients have a higher risk of developing HCC after achieving SVR with DAA. It is important to elucidate the mechanism of the development of HCC after achieving SVR with DAA and to investigate the patients’ characteristics. Thus, the rates of HCC occurrence or recurrence varied from a clinical point of views.
CLINICAL INDICATORS OF HCC OCCURRENCE AND RECURRENCE AFTER SVR BY DAA TREATMENT
HCV-infected patients have a decreased risk of HCC after achieving SVR by interferon treatment[11,22]. Previous studies reported that biomarkers including aspartate aminotransferase (AST), old age, liver cirrhosis and higher posttreatment alpha-fetoprotein (AFP) can predict HCC in patients after interferon therapy. Toyoda et al suggested that an elevated indicator of liver fibrosis, the FIB-4 index at SVR24, is also a predictor of HCC development in SVR patients. The FIB-4 index was a prediction of 5-year survival in HCV infected patients in the interferon-era.
Nguyen et al suggested that AFP decreased significantly from pretreatment (median 7.2 ng/mL) to EOT (4.2 ng/mL) and at 12 wk after treatment (4.2 ng/mL) with DAAs. Liver inflammation increased AFP values in the absence of HCC. Of interest, they suggested that the pattern for normalization of AFP with entecavir showed a shorter period and gradual reduction compared to patients treated with pegylated-interferon.
Similarly, Nagaoki et al showed that serum AFP levels decreased to similar levels at SVR24 both in the pegylated-interferon plus ribavirin and the DAAs treatment groups, and similar rates of HCC development existed in these two HCV genotype 1 infected patients groups (the cumulative HCC development rates after 1-, 3- and 5-years were 1.5%, 10% and 19% and 1.5%, 10% and 12%, respectively). These data suggested the possible reduced potential for HCC development by DAA treatment is as same as that of interferon-based treatment.
Moreover, Tag-Adeen et al showed significant improvement in the FIB-4 index after achieving SVR by DAA in HCV genotype 4 infected patients. However, they also showed that achieving SVR did not guarantee improvement in cirrhosis (61% of cirrhotic patients showed liver stiffness > 12.5 kPa), and cirrhotic patients still had a risk for HCC development despite achieving SVR by DAA. Thus, from the clinical point of view, several liver fibrosis markers may be helpful for the early detection of HCC occurrence and recurrence.
CHANGE IN CYTOKINES AND CHEMOKINES IN HCC OCCURRENCE AND RECURRENCE AFTER SVR BY DAA TREATMENT
Previous reports suggested that DAA changes the cytokine/chemokine levels compared to the pretreatment levels, and it may be related to hepatocarcinogenesis. Sung et al investigated the level of type I interferon, interferon-β in HCV genotype 1b infected patients. Type I interferons bind to a common cell surface receptor, resulting in the activation of the Jak-STAT signal transduction system. Interferon-β may be important not only to prevent patients with acute hepatitis C from developing chronic infection but also to reduce the risk of HCC. After DAA treatment, the expression levels of interferon-β, interferon-induced protein 44 (IFI44) and C-X-C motif chemokine ligand 10 (CXCL10) significantly decreased and rapidly normalized at EOT in the peripheral blood mononuclear cells (PBMCs). IFI44 and CXCL10 correlated with the pretreatment expression level of interferon-β.
Carlton-Smith et al exhibited similar interferon-stimulated gene results in PBMC at treatment week four and EOT and showed a reduction in CXCL10, CXCL11 and macrophage inflammatory protein (MIP)-1β levels. Hengst et al suggested that the expression level of 22 cytokines/chemokines including type I interferon and CXCL10 decreased significantly from baseline to 12 wk after treatment by DAA treatment in patients with HCV genotypes 1, 2, 3 and 4. CXCL10 level was increased in interferon-based therapies by the responsiveness to interferon. In contrast, the interferon system, including CXCL10, is not increased during DAA treatment. A similar effects were also observed in patients infected with HCV genotype 2 or 3 who were treated with DAA. The interferon-stimulated intrahepatic and peripheral gene expression declines with HCV eradication.
DAA treatment increased the serum vascular endothelial growth factor (VEGF) level[37,38], and it remained stably elevated at the 3-mo follow-up. These were observed in patients with HCV genotypes 1a, 1b, 2, 3 and 4. VEGF was significantly related to the serum angiopoietin-2 level, and angiopoietin-2 expression in HCC or in cirrhotic tissue before DAAs was related to the risk of HCC recurrence or occurrence. They showed that the extremely high expression of angiopoietin-2 in recurrence of HCC and de novo HCC had its counterpart in the increased levels of circulating VEGF during DAA therapy. Therefore, they suggested that the interaction between the local overexpression of angiopoietin-2 by the slow blood flow of portal hypertension arising through the progression of chronic liver damage and circulating VEGF is a risk factor for developing HCC that is linked with the advanced stage of cirrhosis in patients treated with DAAs.
Tumor necrosis factor (TNF)-α, known as an important inflammatory mediator that induces immune responses, was originally found to induce tumor lysis. TNF induces the cellular apoptosis of hepatoma cell lines and HCV core and NS5A proteins block TNF-induced cellular apoptosis[39,40]. TNF-α related apoptosis-inducing ligand (TRAIL) also induces the apoptosis of human hepatic stellate cells and HCV blocks TRAIL-induced cellular apoptosis. Spaan et al reported that there is down-regulation in TRAIL-mediated killing by NK cells during DAA therapy in patients infected with HCV genotype 1b. Further studies will be needed. Thus, rapid changes in several cytokines and chemokines are observed during and after DAA treatment and may have several effects on HCC occurrence and recurrence.
IMMUNOLOGICAL MECHANISMS OF HCC OCCURRENCE AND RECURRENCE AFTER SVR BY DAA TREATMENT
Several reports showed that a rapid decreased or normalized immuno-surveillance causes early HCC recurrence or occurrence after DAA therapy. The activating receptor natural killer group 2, member D (NKG2D) and its ligands play a crucial role in the immune response to HCC. Reduced NKG2D ligand expression in HCC correlates with early recurrence. NKG2D predicts the early emergence of HCC after interferon-free DAAs.
Major histocompatibility complex class I-related chain A (MICA), which is one of the human ligands of NKG2D, has been known to be a key molecule in viral HCC immune surveillance, as the interaction with NKG2D triggers NK cell-mediated cytotoxicity toward the stressed cells[45,46]. Moreover, HCC sheds membrane-bound MICA as soluble MICA and down-regulates the expression of NKG2D on the NK cell surface because escape immune surveillance. Chu et al reported that 12% of DAA-treated HCV genotype 1 infected patients developed HCC recurrence or occurrence within 24 wk after EOT. They suggested that a rapid decrease in NKG2D levels at EOT correlated with early HCC emergence in DAA-treated patients. Of interest, this phenomenon was not found in patients treated with the interferon-based regimen. These data may suggest a risk of early HCC after interferon-free DAA treatment, different from interferon-based therapy. Golden-Mason et al reported that the frequency of clusters of differentiation (CD) of 56bright immature NKs decreased 2 wk after DAA therapy started and was maintained at SVR12 in HCV genotype 1 infected patients. Moreover, the downregulation of receptors of cytotoxic signaling including TRAIL, NKp30 and NKp46, was observed 12 wk after DAA therapy started and was maintained at SVR12. They suggest that rapid viral clearance induced by DAA therapy normalizes NK cell function and reduces cytotoxic activity.
The other mechanism was explained by the numbers of peripheral FOXP3+CD25+CD4+ regulatory T cells. In their report, peripheral CD4+ T cells numbers persisted in DAA treatment groups even approximately 51 wk after EOT in HCV genotype 1 infected patients. In HCV genotype 1a/1b patients, DAA therapy reduced the T-cell compartment in the peripheral blood and re-differentiation of the T lymphocyte memory compartment and resulted in a reduction in the expression of the coinhibitory molecule T cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains (TIGITs) in bulk T lymphocytes. They reported that HCV eradication after DAA therapy involves immune reconstitution. These immune reconstitutions may support the successful treatment of oral lichen planus after DAA therapy. Thus, rapid immunological changes, including in NKG2D systems are observed during and after DAA treatment, and they may have several effects on HCC occurrence and recurrence.
HOST GENETIC FACTORS OF HCC OCCURRENCE AND RECURRENCE AFTER SVR BY DAA TREATMENT
In the interferon era, genome-wide association studies (GWAS) identified that several genetic variants in close proximity to interleukin 28B (IL28B; also known as interferon-lambda 3) variants were strongly associated with the response to pegylated-interferon-α plus ribavirin therapy for chronic HCV infected patients[52-54]. Moreover, IL28B variations are independent predictors of the progression of hepatic fibrosis[55,56] and seems to be involved in the hepatocarcinogenesis[57,58]. However, with the induction of interferon-free regimens, the importance of IL28B genetic variants may be diminishing in HCV genotype 1 infected patients. There have been some reports that showed the relation between single nucleotide polymorphisms (SNPs) and hepatocarcinogenesis.
Lange et al revealed a SNP in HLA complex P5 (HCP5) rs2244546, which is a upstream of MICA, as a strong predictor of HCV-related HCC. The differentially methylated cytosine-phosphate-guanine (dmCpG) loci were also reported. The dmCpG loci were highly enriched for enhancers, promoters, or CpG islands and the surrounding regions and were hypermethylated in HCC infected with HCV. The dmCpG loci were associated with cellular growth and proliferation although this report has several limitations.
Of interest, Matsuura et al investigated GWAS data on hepatocarcinogenesis specifically in HCV-infected patients after the eradication of HCV by interferon-based therapy. There was no difference of development of HCC in HCV genotype 1 or 2 infected patients after eradication of HCV. They found a strong association between the SNP rs17047200, located within the intron of the tolloid like 1 gene (TLL1) on chromosome 4, and the development of HCC, and it played a role in hepatic fibrogenesis. It is uncertain whether interferon-free therapy can inhibit TLL1 after the eradication of HCV. Future studies are needed to evaluate this point.
HCV-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway. MicroRNAs associated with HCV-related immunopathogenesis which were found to be enriched in exosomes of HCV viremic patients (in particular, miR-122-5p, miR-222-3p, miR-146a, miR-150-5p, miR-30c, miR-378a-3p and miR-20a-5p), were markedly reduced by DAA therapy. Enrichment of immunomodulatory microRNAs in exosomes of HCV patients was correlated with their inhibitory activity on innate immune cell functions. DAAs against HCV may have an impact on extracellular vesicles including microRNAs, leading to immunomodulation. Thus, several host genetic factors and microRNAs are change during and after DAA treatment, which may have several effects on HCC occurrence and recurrence.
DAA therapy is more efficacious for HCV eradication with fewer side effects. The use of DAAs does not increase the occurrence or recurrence of HCC according to clinical trials. However, the mechanism that altered the immunological balance because of a rapid decrease of HCV viral load in the short-term after DAA therapy may contribute to early tumor development (Figure 1). Sasaki et al demonstrated the changes of complement cascades and neutralizing antibodies after SVR by DAA. Complement-dependent cytotoxic effects and neutralizing antibodies are also important for HCC cells survival. Thus, a longer follow-up period and basic research are required to establish whether there is a risk or advantage of HCC recurrence or occurrence with interferon-free therapy. Moreover, new serum biomarkers that may be altered by DAA therapy should be investigated in the follow-up of HCV-patients with SVR after DAA and interferon-based regimens.
Figure 1 Emergence of hepatocellular carcinoma (HCC) during and after treatment in direct-acting antiviral (DAA) era (upper part) and intreferon era (lower part).
It is uncertain whether HCC emerges in patients treated with DAA in more than 5 years after sustained virological response. DAA: direct-acting antiviral; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; ISG: interferon-stimulated gene.
Manuscript source: Invited manuscript
Specialty type: Gastroenterology and hepatology
Country of origin: Japan
Peer-review report classification
Grade A (Excellent): A, A
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0
P- Reviewer: Carneiro BM, Pandey VN, Arriagada GL S- Editor: Dou Y L- Editor: A E- Editor: Tan WW